Billerica, Massachusetts, March 21, 2017 — MilliporeSigma , a leader in single-use technology, today launched an industry first — the Mobius® MyWay portfolio, a program that allows more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.
“We have the industry’s only comprehensive single-use solution, giving customers three different ways to create customizable assemblies,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, MilliporeSigma. “This is critical to customers from contract manufacturing organizations to big pharma, whose biggest challenge is getting custom assemblies with fast, reliable lead times for quicker turnarounds and more rapid biomanufacturing.”
For commercial manufacturers, MilliporeSigma’s Mobius® MyWay portfolio helps minimize schedule disruptions and delays. Pilot plants benefit from faster assembly design and delivery in order to adjust to new and evolving needs in real-time. Contract manufacturing organizations benefit from more reliable lead times allowing for better planning, which helps ensure on-time product delivery.
MilliporeSigma’s portfolio offers a choice of off-the-shelf and configured-to-order assemblies, as well as fully customizable configurations. Assemblies available as part of the Mobius® MyWay portfolio are used for safe and effective fluid management across upstream and downstream processes, from routine buffer and media prep, to critical premium aseptic process and final drug manufacturing.
Assemblies are segmented into three categories, each offering a different level of configuration flexibility:
Among the assemblies included in the Mobius® MyWay portfolio are Mobius® MIX systems and bags up to 1,000 liters; holding and transport vessels up to 3,500 liters; Lynx® CDR sterile connectors and single-use final formulation, filtration and final fill assemblies.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.